Literature DB >> 27387986

Extranodal extension of lymph node metastasis is a marker of poor prognosis in oesophageal cancer: a systematic review with meta-analysis.

Claudio Luchini1, Laura D Wood2, Liang Cheng3, Alessia Nottegar4, Brendon Stubbs5, Marco Solmi6, Paola Capelli4, Antonio Pea7, Giuseppe Sergi8, Enzo Manzato8, Matteo Fassan8, Fabio Bagante7, Elfriede Bollschweiler9, Simone Giacopuzzi10, Takuma Kaneko11, Giovanni de Manzoni10, Mattia Barbareschi12, Aldo Scarpa13, Nicola Veronese8.   

Abstract

The extranodal extension (ENE) of nodal metastasis is the extension of neoplastic cells through the nodal capsule into the perinodal adipose tissue. This histological feature has recently been indicated as an important prognostic factor in different types of malignancies; in this manuscript, we aim at defining its role in the prognosis of oesophageal cancer with the tool of meta-analysis. Two independent authors searched SCOPUS and PubMed until 31 August 2015 without language restrictions. The studies with available data about prognostic parameters in subjects with oesophageal cancer, comparing patients with the presence of ENE (ENE+) versus only intranodal extension (ENE-), were considered as eligible. Data were summarised using risk ratios (RRs) for number of deaths/recurrences and HRs together with 95% CIs for time-dependent risk related to ENE+, adjusted for potential confounders. Fourteen studies were selected; they followed-up 1437 patients with oesophageal cancer for a median follow-up of 39.4 months. The presence of ENE was associated with a significantly increased risk of all-cause mortality (RR=1.33; 95% CI 1.18 to 1.50, p<0.0001, I2=49%; HR=2.72, 95% CI 2.03 to 3.64, p<0.0001, I2=0%), cancer-specific mortality (RR=1.35; 95% CI 1.14 to 1.59, p=0.001, I2=57%; HR=1.97, 95% CI 1.41 to 2.75, p<0.0001, I2=41%) and of risk of recurrence (RR=1.50, 95% CI 1.20 to 1.88, p<0.0001, I2=9%; HR=2.27, 95% CI 1.72 to 2.90, p<0.0001, I2=0%). On the basis of these results, in oesophageal cancer, ENE should be considered from the gross sampling to the pathology report, and in future oncological staging system. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/

Entities:  

Keywords:  CANCER; METASTASIS; OESOPHAGUS

Year:  2016        PMID: 27387986     DOI: 10.1136/jclinpath-2016-203830

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  11 in total

1.  Extranodal extension of nodal metastasis is the main prognostic moderator in squamous cell carcinoma of the esophagus after neoadjuvant chemoradiotherapy.

Authors:  Claudio Luchini; Nicola Veronese
Journal:  J Thorac Dis       Date:  2017-10       Impact factor: 2.895

Review 2.  Extranodal extension of nodal metastases is a poor prognostic moderator in non-small cell lung cancer: a meta-analysis.

Authors:  Claudio Luchini; Nicola Veronese; Alessia Nottegar; Monica Cheng; Takuma Kaneko; Camilla Pilati; Fabrizio Tabbò; Brendon Stubbs; Antonio Pea; Fabio Bagante; Jacopo Demurtas; Matteo Fassan; Maurizio Infante; Liang Cheng; Aldo Scarpa
Journal:  Virchows Arch       Date:  2018-02-01       Impact factor: 4.064

Review 3.  Data set for the reporting of pheochromocytoma and paraganglioma: explanations and recommendations of the guidelines from the International Collaboration on Cancer Reporting.

Authors:  Lester D R Thompson; Anthony J Gill; Sylvia L Asa; Roderick J Clifton-Bligh; Ronald R de Krijger; Noriko Kimura; Paul Komminoth; Ernest E Lack; Jacques W M Lenders; Ricardo V Lloyd; Thomas G Papathomas; Peter M Sadow; Arthur S Tischler
Journal:  Hum Pathol       Date:  2020-05-11       Impact factor: 3.466

Review 4.  Extranodal extension of lymph node metastasis influences recurrence in prostate cancer: a systematic review and meta-analysis.

Authors:  Claudio Luchini; Achim Fleischmann; Joost L Boormans; Matteo Fassan; Alessia Nottegar; Paola Lucato; Brendon Stubbs; Marco Solmi; Antonio Porcaro; Nicola Veronese; Matteo Brunelli; Aldo Scarpa; Liang Cheng
Journal:  Sci Rep       Date:  2017-05-24       Impact factor: 4.379

5.  Prognostic Implications of Extranodal Extension in Relation to Colorectal Cancer Location.

Authors:  Chan Wook Kim; Jihun Kim; Yangsoon Park; Dong-Hyung Cho; Jong Lyul Lee; Yong Sik Yoon; In Ja Park; Seok-Byung Lim; Chang Sik Yu; Jin Cheon Kim
Journal:  Cancer Res Treat       Date:  2018-11-29       Impact factor: 4.679

6.  Impact of Extranodal Extension on Risk Stratification in Papillary Thyroid Carcinoma.

Authors:  Hye In Kim; Jiyeon Hyeon; So Young Park; Hyeon Seon Ahn; Kyunga Kim; Ji Min Han; Ji Cheol Bae; Jung Hee Shin; Jee Soo Kim; Sun Wook Kim; Jae Hoon Chung; Tae Hyuk Kim; Young Lyun Oh
Journal:  Thyroid       Date:  2019-05-30       Impact factor: 6.568

7.  Extranodal extension status is a powerful prognostic factor in stage III colorectal cancer.

Authors:  Chan Wook Kim; Jihun Kim; Seung-Seop Yeom; Jong Lyul Lee; Yong Sik Yoon; In Ja Park; Seok-Byung Lim; Seunghee Baek; Chang Sik Yu; Jin Cheon Kim
Journal:  Oncotarget       Date:  2017-05-26

8.  Detection of metastatic cancer cells in mesentery of colorectal cancer patients.

Authors:  Xue-Lai Luo; Da-Xing Xie; Jian-Xin Wu; An-Ding Wu; Zong-Qing Ge; Hai-Jie Li; Jun-Bo Hu; Zhi-Xin Cao; Jian-Ping Gong
Journal:  World J Gastroenterol       Date:  2017-09-14       Impact factor: 5.742

Review 9.  Ampulla of Vater carcinoma: Molecular landscape and clinical implications.

Authors:  Antonio Pea; Giulio Riva; Riccardo Bernasconi; Elisabetta Sereni; Rita Teresa Lawlor; Aldo Scarpa; Claudio Luchini
Journal:  World J Gastrointest Oncol       Date:  2018-11-15

10.  Assessment of intratumor immune-microenvironment in colorectal cancers with extranodal extension of nodal metastases.

Authors:  Matteo Fassan; Luca Vianello; Diana Sacchi; Giuseppe N Fanelli; Giada Munari; Marco Scarpa; Rocco Cappellesso; Fotios Loupakis; Cristiano Lanza; Roberta Salmaso; Claudia Mescoli; Nicola Valeri; Marco Agostini; Edoardo D'Angelo; Sara Lonardi; Salvatore Pucciarelli; Nicola Veronese; Claudio Luchini; Massimo Rugge
Journal:  Cancer Cell Int       Date:  2018-09-06       Impact factor: 5.722

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.